论文部分内容阅读
目的对比研究瑞替普酶与阿替普酶在肺栓塞溶栓治疗中的临床疗效及安全性。方法 50例符合溶栓治疗的急性肺动脉栓塞患者,26例给予瑞替普酶,24例给予阿替普酶溶栓。分别观察溶栓前及溶栓4h后患者的临床表现、心率、血气分析、3d后螺旋CT肺动脉成像的变化及出血等不良反应,比较二者的溶栓效果。结果应用瑞替普酶对急性肺栓塞溶栓后有较好的疗效,未见严重的不良反应。结论应用瑞替普酶对急性肺动脉栓塞进行溶栓有较好的临床疗效及安全性,等同于阿替普酶。
Objective To compare the clinical efficacy and safety of reteplase and alteplase in thrombolytic therapy of pulmonary embolism. Methods Fifty patients with acute pulmonary embolism who underwent thrombolytic therapy, 26 received reteplase, and 24 received alteplase thrombolysis. The clinical manifestations, heart rate, blood gas analysis, changes of pulmonary CT angiography after 3 days and bleeding and other adverse reactions were observed before thrombolysis and 4h after thrombolysis. The thrombolytic effects of the two drugs were compared. Results The application of reteplase on acute pulmonary embolism after thrombolysis has a good effect, no serious adverse reactions. Conclusion The application of reteplase for acute pulmonary embolism thrombolysis has better clinical efficacy and safety, equivalent to alteplase.